论文部分内容阅读
目的探讨巨噬细胞集落刺激因子(M-CSF)在131I治疗Graves′病中的价值。方法应用酶联免疫吸附试验(ELISA)法测定Graves′病患者,以及Graves′病患者131I治愈后的M-CSF水平,同时与健康人比较;分析M-CSF水平与游离甲状腺素(FT4)浓度之间的相关性。结果Graves′病患者M-CSF水平显著高于健康人,与治疗前比较差异有统计学意义(P<0.05),Graves′病患者131I治愈后的M-CSF水平呈降低,差异有统计学意义(P<0.05);M-CSF水平与FT4浓度呈正相关(r=0.58,P<0.05)。结论M-CSF可以作为131I治疗Graves′病的疗效观察指标。
Objective To investigate the value of macrophage colony stimulating factor (M-CSF) in 131I treatment of Graves’ disease. Methods The levels of M-CSF in patients with Graves ’disease and Graves’ disease were measured by enzyme-linked immunosorbent assay (ELISA), and compared with healthy controls. The levels of M-CSF and free thyroxine (FT4) The correlation between. Results The level of M-CSF in patients with Graves ’disease was significantly higher than that in healthy people (P <0.05), and the level of M-CSF in patients with Graves’ disease was lower after 131I treatment, the difference was statistically significant (P <0.05). The level of M-CSF was positively correlated with FT4 concentration (r = 0.58, P <0.05). Conclusion M-CSF can be used as 131I treatment of Graves’ disease efficacy indicators.